Felipe Couñago/X
May 6, 2025, 06:43
Felipe Couñago: Dirk De Ruysscher presented a model predicting futile CRT in stage III NSCLC at ESTRO25
Felipe Couñago, National Clinical Director of GenesisCare Spain, shared a post on X:
“At ESTRO2025, Dirk De Ruysscher presented a model predicting futile CRT in stage III NSCLC. High-risk patients (early mortality) may benefit from upfront immunotherapy instead. A step toward personalized treatment.”
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the David Geffen School of Medicine at UCLA, shared a post by Felipe Couñago, adding:
“This is meaningful. Pts with tumors that are big to resect, or who are very frail, are often referred to radonc who feel compelled to treat. It’s crucial to consider upfront systemic treatments and revisit 3-4 months later to avoid delivering anything futile.”
More posts featuring ESTRO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 19:09
May 29, 2025, 17:58
May 29, 2025, 17:45